Hi everyone, Joe for jazzy's casebreaks.com with 2022 mosaic basketball hobby pack random team number three, the last filler we got to do to unlock that obsidian random number block. There were full spots left in that random number block that sold out. That's going to unlock that randomizer for the number block and that unlocks the obsidian football break. So a lot of nice things happening there. Big thanks to this group for making it happen, appreciate it. And all 32 teams are in. So we're going to do the pack break first different dice roll for the random number block giveaway. All right. So for this three and a five eight times for names and teams one, two, three, four and different dice roll for the great credit giveaway. That's something else for the number block giveaway seven and once more eighth and final time three and a five eight times for the teams one, two, three, four, five, six, seven and eight. All right. No trade windows in these like filler pack breaks. That's not something we're going to do. We want to get to the more important part, which is the, which is the giveaway part. So here's the first part of the list. There's the second half of the list right there. And let's print and rip. It's not printing. All right. And it looks like that flawless collegiate is sold out. Nice. And Ed P gets a full spot in that hit parade and gets a full spot in the flawless collegiate and Richard gets two in the flawless collegiate and Craig bought the last spot mojo and flawless collegiate. Nice. Thanks everybody. So that breaks going to happen and we'll run an abbreviated break credit promo. All right. There's the final print out here. You know, we, we also accept a, if you're having trouble with PayPal, Charles, we also accept a just regular creditor debit card as well. We're going to get a hit in here, maybe no, I don't think so. All right. So nothing too crazy there, but not three big hits here. Those are the $200 random number block spots. Let's gather all the names one through 32 dice list and let's roll and randomize it six into two eight times. It's going to be top three after eight. So it's only three out of three. There's going to be a lot of sad faces here, but the top three are going to be very happy after eight times. Good luck. Six into two. One, two, three, four, five, six, seven and eighth and final time after eight. Now from, it's only the top three. So from four on down, it's going to be sad times. Terry with that last bottom mojo, sad times, four through 32, everyone's sad on that list, but only the top three are going to be happy. That's going to be Jason K is happy, Chad is happy and Robert is happy. Congrats to the top three. Thanks everyone else for giving it a shot. We'll get them next time. Thanks everyone. JaspeysCakesPrix.com


The Oceans State Ward Congress of the All Progressive Congress, a big apart in APC, was mainly affirmation which produced consensual members of executive across the state. APC party members gathered at different wards in the state to witness affirmation of the executives. Our correspondent, Ola Shukomi Ogumuko, completes this report. Grassroots democracy is the bedrock of any democratic development. Deepening such bedrock is the reason these party members in Oceans state are here to witness the making of the party structure of the All Progressive Congress APC from the base, ward to ward, in all the local governments. A party member who monitored the Congress in some of the wards in Oshibu and Olorunda local government areas of the state, Boyega Adelabu, describes the process as hitch-free and devoid of rancor. International democracy of party is the beginning of a very good democracy and that is what we are trying to do today. We are trying to relate our world and as suggested by national body that most of the state we should try and do consensus and as agreed by the stakeholders of our party in Oshibu state yesterday which was a governor in the Shukunaka government what we are doing is consensus and I can tell you everybody is happy we have we have monitored forward and I can tell you always we have done these processes. However parallel congress was adopted by some of the party members who belong to a group called the Oceans Progressives, TOP at Ward 1 at Tawaja A area of the state. Lowmaker representing Oceans Central Senator Ajibo Labashiri who said the consensus was a combination of efforts of stakeholders at national state, local government and world levels. There is no parallel congress. There is a single world congress committee headed by Honorable Benga Elebeleye and the deployed TV-TV band committee to conduct congress. Ask anybody that says he has conducted parallel congress. From where did they get the power to conduct parallel congress? There cannot be parallel congress because there is a unity structure headed by Honorable Benga Elebeleye that believe your crew was at the government house yesterday when they were briefed. For you to conduct a congress, luckily the congress it must have been so and in our world for instance only one set of form was collected because no other person's signified interest to contest against our people. The whole line at the back of the candidates and all the members were counted and the first man Taufik Ishala won 167 people at his back. Why the other one, Mashu Davalabi, won score 31 and the total number is 198 all together. Now that the congress have come and gone, what is left is how party members especially at the grassroots can bury the hushed in managing their internal democracy to achieve a formidable front for the gains of a truly democratic dispensation. Hello, hope you enjoyed the news. Please do subscribe to our YouTube channel and don't forget to hit the notification button so you get notified about fresh news updates.


Good afternoon, everyone, and thank you so much for joining us for a really important conversation today about the vaccine rollout. We're here. Thanks to the public interest technology program at New America and Future Tense, which is a collaboration of New America slate magazine and Arizona State University that explores the intersection of technology policy and society. I'm Tori Bosch the editor of Future Tense and I'm so honored to be here today. We have an awful lot to discuss in only an hour so I'm just going to jump in and introduce our three speakers for the afternoon. First we have Dr. Helene Gale who has been president and CEO of the Chicago Community Trust since 2017. There she focuses on closing the racial and ethnic wealth gap in Chicago. She previously served as president and CEO of care, a leading international humanitarian organization. She has worked on global development, humanitarian and health issues. Dr. Gale spent 20 years with the Centers for Disease Control and Prevention, working primarily on HIV AIDS. She has also worked at the Bill and Melinda Gates Foundation and the McKinsey social initiative, which is now known as McKinsey.org. And she also serves on numerous committees and nonprofit boards and holds faculty appointments at both the University of Washington and Emory University. Thank you for being with us. I'm joined by Dr. Atul Gawande. Dr. Gawande is a surgeon, writer and public health researcher. He's practiced general and endocrine surgery at Brigham and Women's Hospital since 2003. And is a professor in both the Department of Health Policy and Management at the Harvard School of Public Health and the Department of Surgery at Harvard Medical School. He's also the executive director of Ariadne Labs, a joint center for health systems innovation at Brigham and Women's Hospital and Harvard School of Public Health. He's also been a staff writer for the New Yorker since 1998 and has written four New York Times bestselling books, Complications, Better, The Checklist Manifesto, and Being Mortal. And though it's not noted on his official biography, he also spent some time writing for Slate where Future Tenses based as well. And finally, we have Hannah Shang. Hannah is the strategy director for public interest technology at New America, where she works to develop public interest tech via research, storytelling and hands-on projects. Previously, as a part of the US Digital Service, Hannah was a director with the Department of Homeland Security. She is a frequent contributor to national publications and the author of three books. Her forthcoming book on solving public sector problems in the digital age will be published by Princeton University Press this April. So the four of us will be speaking for about 40 for 45 minutes, and then we'll open it up to Q&A. You can submit your questions at any point in the conversation using the Q&A function, though I don't know why I'd rather to say that since we are all very familiar with the Zoom interface at this point. So thank you again all for being here. Dr. Gail Haline, I would like to start by asking you to tell us a little bit about the work you did on the National Academies Committee to come up with an ethical framework for distribution of the vaccine. Great. Thank you very much. And I just want to point out one fact that you forgot for both Atul and me that we're both board members of New America. So I'm so sorry. I don't know why that's written in the bios I was looking at. But anyway, we're proud of our affiliation. So anyway, so, you know, I was one of the co-chairs this summer for the report that you mentioned that the National Academies of Science, Engineer and Medicine was asked to do by CDC and NIH and as many people know the National Academies functions to put out independent reports for tough and important social and scientific issues. And at the time that we were asked this was before there was any vaccine that had been authorized, and it was in the face of a lot of unknown. So, you know, we were asked to pull this together though because we knew that there would be a scarcity when the vaccine was first developed and that it was important to have a framework that would guide that. And so we had a committee of 13, 14 people of all different backgrounds, all different disciplines to really do the best we could in the midst of a lot of uncertainty to develop a national framework that would then be used by other policymakers, primarily the committee that advises CDC, the ACIP that advises CDC on utilization of vaccines once they're developed. We put together a framework and I would just point out that, you know, for us it was very important that this was this framework was grounded in some core values, and then developed a risk framework that really looked at the risk factors that were characteristic of this particular pandemic because as we know every pandemic has its own kind of personality and wanted this to be very specific. So, we had some foundational principles that we think related to this particular situation one that there should be maximum benefit in thinking about the allocation given the impact that it had not just on health but also on society that there should be equal concern because we know that the populations that were most impacted often didn't have the social status in, you know, think essential workers your, you know, low wage earning health workers, etc. But we really wanted to make sure that there was nothing about where you fit in society that dictated where whether or not you had access and that they're that mitigation of health inequities was incredibly important giving the disproportionate impact that it had on communities of color. So we looked at a risk framework that we thought characterized the most important risk the risk of acquiring or transmitting the infection, the risk of severe disease or or morbidity, and the risk of negative societal impact again because of the huge overall impact that it had. And by using that risk categorization came up with the four phases that you know that we developed a phase one that had a one a and one b phase two phase three phase four with the idea that this is a vaccine that ultimately everyone should have access to, but in the face of scarcity, needing to access different phases. We also said that again, given the focus on equity and the fact that communities of color particularly had been disproportionately impacted. We said that across all of the phases. There should be priority to the geographic areas that were highest on the social vulnerability index. That's the index that CDC has developed that looks at issues related to race, ethnicity, access to transportation household configuration and all the things that put one at greater risk for epidemic disease or other natural disasters and that there should be priority geographically across all those phases. So that in a nutshell, I won't go into all of the phases because we've, you know that that has now become something that people talk a lot about. And we never thought that the phases should be that they should be that there should be some flexibility which we've seen states have looked at phases in different ways but we did feel like those basic core principles and looking at this from a risk framework would actually help us get to the people who needed this the most, and that it would be a more equitable way of distributing a scarce resource. That's fantastic and I want to come back to the way this is all played out among the states, how this is aligned with what you were hoping for and has not. But first I want to get to the fact that this vaccine rollout of course or these vaccine rollouts have coincided with a pretty momentous change in administration in the US. Atul, I know that you served as an advisor to the Biden administration's transition team on COVID matters. Could you talk a little bit about how the Biden administration was approaching the fact that they were coming into this in the midst of a process that was already underway. Yeah, it was made complicated by a couple of things one is clearly coming in at mid course which meant that making major changes. For example, you know, there wasn't a lot of centralized software development the way that you would love to have seen, but now changing a pathway where everybody's on a different system is the way it is right and and trying to up and all of that is going to do. Second, was the lack of good information. So, you know, there are several things about vaccine rollout. Besides what the supply situation is, you want to know about the supply chains you want to know about staffing and what what the federal strategy policies are to make it so you have enough vaccinators. You need to know what you're going to do about software you need to know what you're going to be able to do around billing and resources and enabling all of that. So, I found in two ways both during the transition and talking to many states and and companies involved, but then also in Massachusetts, I am founder of a organization called CIC health that has been behind mass facts that mass testing, and mass vaccination and seeing on that and we run Gillette and Fenway Park and a place called Reggie Lewis track and field, which will be taken over management next week in in Roxbury the those problems of just all the nuts and bolts. There were, there were, they are a source of costs, a source of slowing things down. And that planning had not been in place should have been four or five six months. And so suddenly you're compressing into, you know, post Thanksgiving, trying to stand these things up in three weeks or four weeks and that was clearly Herculean and we're still just in the catch up mode right now. And it was something I was actually wanting to ask you all about, you know, there's certainly a lot of criticism about the rollout and, you know, I think probably extremely justifiably but a question I had is, to what extent are the problems, a lack of poor planning and to what extent are they just that this is all really really hard. Well, it is the poor planning. I agree with Helen. It's a combination of both. But I think that the thing you're getting at is, we're now, you know, about eight weeks from that point where people really got things underway, and the vaccine rollout is now moving at a significant speed, you know, we have 1.7 million vaccines now per day would have loved to have seen us ready to do that in December. We lost a lot of ground. But you know, now that means that we have around 40 million people who've been vaccinated as of today. We've just popped into the top five big countries for our ability to roll it out and that's despite a really broken fragmented health care system where you've had to build a lot of new capabilities that weren't there before. Yeah, I'll just add to that to say, I mean, I think this clearly this would have been hard regardless. And, you know, it would have been ideal to have more national planning. A systematic approach, more consistency across all states, less guesswork, all of the things that we know we went into this with. That said, this is hard. It's the, you know, this is the most complicated public health endeavor we, you know, any of us have been vaccinated for generations and generations before that. And I think it does highlight the fact that, you know, we still don't adequately resource our public health infrastructure. Nor are we what were we well prepared for an adult vaccination program, you know, we do childhood vaccinations really really well. We don't do adult vaccination we know that flu vaccine rates are not as high as they need to be and so I think, you know, I hope that coming out of this we will really take seriously the charge to fund our public health infrastructure and think about what does it take to have a functioning public health infrastructure that also serves adult vaccination because this is not going to be the last time we're going to need it. So I'm curious, Haline just following up on something on so you talked about the development of the risk framework. And so I live in New York City, where we are just plowing through phase one phase two we're now up to as of yesterday, people with comorbidities and a citizen and also someone who understands what's happening on the inside of government. There's, we haven't finished vaccinating people in the other risk categories we've just moved on because not enough people are can get to the vaccines anyway so it seems like on the inside. They kind of thought, well we'll just, you know, open it up and see what happens. So I'm curious if just sort of seeing how that's played out if there is anything that you think the CDC should have done differently in providing the risk framework just around and obviously I don't know like what level of guidance the state's got but we'd love to know your thoughts on that. Yeah, I don't think it's as much the risk framework. We, we know that, you know, throughout this, that people who have had greater access to internet for instance when you need to find a vaccine site or use the internet to be able to make appointments have had, you know, and, and all of the things, people who have greater access to health services to begin with, you know, have had greater access to, to the vaccine. And I guess there's a balancing act between the speed and getting as many people vaccinated as possible, versus making sure that we vaccinate the people who need it the most, because, you know, on, on one hand we want as many people vaccinated as possible. On the other hand, from a standpoint of minimizing harm and also minimizing the risk of spread, you go where the disease is most prevalent, you go where the impact is greatest and that's how you'll also have the greatest impact overall. But I think we're constantly balancing that because of the realities of the inequity that exists in our country in our health systems, and we want to get people vaccinated. So I think we, we need to think about what will it take for people who come from low resource backgrounds, where, or populations where there is vaccine hesitancy for a variety of different reasons. How are we making sure that we're putting the kind of effort into those areas, so that we don't have a lopsided and we're rolling things out without thinking about the, the people who have born the greatest burden of this, and where the infection has taken the greatest hold so I think it's a, it's a balancing act. I'll jump in a little bit on this one. It's interesting. There are, to me, has been how how much the state rankings about how fast they're moving the vaccine have driven the conversation in every state. And so the desire to move fast and efficiently to get as many of the vaccines out has sort of been paramount. I, I can't totally criticize it because of the need to, you know, this has been all about getting the people who are over 75 plus the people of two comorbidities who are the groups who are, you know, at greatest risk of dying, everybody was on board with Helene, you know, your, your team identifying early on that healthcare workers nursing homes and then first responders should go in the, in the first group, and then that we got to get to these high risk folks right away. The parsing out within them, you know, should we do all the 75 year olds before we get to the 65 year olds. That's been quite variable in Massachusetts in contrast from New York. You know, we had gotten, we'd open up to the 75 year olds, found that you got to 200,000 out of the 430,000 in the state very quickly. And then where other places would have then gone to the 65 year olds and the people with two core comorbidities, the determination was wait we haven't got to the other 230,000. And, and so there's been a lot of effort to move to those groups 75 it's made people in the 65 to 74 year old age group very angry about not having access. And it's required all the creativity that Helene's talked about to get to the, you know, to the folks who aren't coming out of their homes to take the vaccine aren't signing up, because it's online because it's because they haven't, you know, gotten the message because they don't have a three kids who are able to stand by their computer all day and, or make 100 phone calls to get in through the two different places. And the, the one creative thing that came out of it which has also gotten a certain amount of fire is the governor here said if you bring in somebody who is over 75 and get them vaccinated you will get vaccinated too. And that's led to people putting on Craigslist I'll pay you $200 if you're over 75 and need your vaccine. You know, I think it's incredibly creative because it's getting people with means to work to get the people without means in through the system. On the other hand, I totally believe we need to be moving fast to get to all of these groups. So we've seen that sort of creativity as you say in Massachusetts, other states have tried other approaches to try to maximize vaccination. But I think we also see a lot of criticism about how much has been left up to this state so I mean I'm curious whether you all think that a more centralized approach might have been better or would that have ended up throttling the sort of creativity that we have seen at a state level. You know, I mean, I, I do think that we suffered from not having a more coordinated approach to this. And the, you know, the role that CDC plays and other national actors, you know, is to give the overarching guidelines to the states. And, you know, public health is a state function. And so states do have the responsibility to its citizens. I think there, there ought to have been and there has been a fair amount of creativity and innovation at the state level. That said, there is a role, I, I believe for a stronger overarching, you know, here's, here are the core things that we will all do that will have a much more coordinated approach. And then within that, you know, allow for individual state innovation that meets the need of a particular state or a particular locality. But I do think that, you know, one of the things that we that we could have and I wish we had had more in the very beginning was a much more national approach. And really when it came to vaccine allocation by states, and you know, some of the just core infrastructure and capacity that is necessary to do this well. I want to ask Hannah, from your US digital service experience, you know, CDC built a centralized scheduling system the states didn't want to go forward it had lots of defects. Do you think that those functions, like the tech should have been centralized more or or is that really, was it just bad execution or is it a bad idea. So the problem with the tech not being centralized from the beginning the way that it should have been the system that the CDC produced was retrofitted for another for different for other users and isn't user friendly and wasn't had a whole bunch of reasons that the states didn't chose not to use it. And that presents a real issue because it's hard to retroactively centralized things like data. I just, I keep thinking every day of all the data that is being missed out on all the data collection that we could be doing at the state level that isn't happening. They're in part because there's no centralized response and all there are all these different systems that are communicating with each other and I'm not even I think what is being captured is really the bare minimum. And I think it's going to be really challenging as we move out of this stage that we're in now where more people are raising their hands to get vaccinated than we have vaccines but at some point, that's going to flip. We're going to need to know well where are the people who have not been vaccinated and the ability to track that at a granular granular level is really dependent upon the data that we're collecting now. So I worry very much about that on a daily basis, but that's going to be really challenging and they are there in the United States digital service is, I believe stepping into this and there's going to be more coordination at the federal level, but I think a lot about what we've already missed. My sense on centralization is that I sort of have to break it down into different categories, I think resources needed to be centralized with, you know, funding coming through and that's starting to flow from the December package but that was late to come out of $8 billion to be required for vaccinators and and getting to the large numbers we're trying to only 300 million was mobilized in the month of December so that was a that was a big hurt. The second clear area is staffing and the hospitals are already stretched we see in our area for example and getting vaccinators that you have to both get, you know, we're going state by state but it could have been a federal that said you don't need to have a nursing degree or a full paramedic training a basic EMT or a pharmacy tech can vaccinate and I'd argue that with appropriate supervision, we could be having lay people being able to vaccinate with the same training it's about three to five hours that we provide to the EMTs, as long as you have the kind of supervisory team available. And FEMA now is starting to supply significant amount of staff and support, as well as standing up vaccination centers and that's a really big deal and, and would have loved to have seen that started, you know, three months ago to five months ago. And on the tech, I think that my sense has been that having clear higher standards around one, you know, data lake which is what we have, and one set of expectations about what information is included, you know, having half the states, not supplying information about race and gender is extremely difficult, you can track by zip code but we can't track by education level to understand where the gaps are. Those kinds of that there's an opportunity to upgrade and set standards there and I'm glad to hear that digital service is potentially tackling that. And I think that having one system that has to enroll take in the massive volume of people there, there, nobody has been ready for this and add in be able to build the billing in. I think another centralized function is why we have to try to arrange for billing for every American from their insurer for $17 for a shot, you're going to spend five six $7 sending the bill. We just have every insurer allocate that you know they're going to hand over the payment for this to a Medicare or a HRSA in HHS to deploy those resources according to who gets, you know, where where vaccinations are being done, I think that could have been centralized more as well. Another thing is just diffusion of innovation because you know clearly a lot is happening across the country and there are ways in which people are learning how to be innovative around this, but there's really no good mechanism for collecting those experiences so that they can be shared. And you know I think a lot of innovation does happen at the local level at the state level, but being able to then scale that up and share that is something that I think would be better to build into the system as well. I mentioned something that we're going to see at some point in the coming months of time when we go from way more people wanting the vaccine, they can get it to people who are more concerned about the vaccine and are less willing to get it. I'm curious, Helene if you could talk a little bit about how you in coming up with the framework thought about the sort of justifiable distrust of the medical community among black and other marginalized communities, and how you think we can best approach equipping people to make a decision that they feel comfortable with there. Yeah thanks and you know, I think we had seven overarching recommendations and I think three of them were around in somewhere the other vaccine hesitancy. You know, and one thing we recommended was that it would be good again thinking about the national level to have a national campaign. You know there has not been anything that sets the general knowledge and information bar for the whole nation and we should be having a national campaign that puts out the facts talks about how these vaccines are developed what the risk or what the experiences etc so that everybody has access to just the core information. You know, secondly, we felt that it was really important, particularly for communities of color but not exclusively but particularly communities where there has been this historic mistrust of government of the medical establishment for very obvious reasons of bias discrimination and real harm that was done to populations that it would be important to also have engagement with communities and really thinking about who are the trusted messengers. What are the best ways to get messages out there and do it in a way that respects people's dignity. And people's ability if given the right information to make the decision that is right for them. You know, we all feel like it is the best thing to do to take the vaccine but people need to feel that themselves they need to feel comfortable with it. They need to feel like this is something that makes sense for them and their families. So really this not this two way communication if you will how are you receiving what people's experiences are, and then how are you actually providing information that's relevant to them by people that they trust. You know, I often say that I think, you know, Dr. Cosmekia Corbett, who helped to create the vaccine, do a lot of the research on the Moderna vaccine at NIH is probably one of the best folks persons because people seeing her, particularly, you know, African Americans seeing this young woman who was part of creating this vaccine brings a sense of okay, I maybe I can trust this because there's somebody like me there's somebody who I trust, somebody who I think, you know, has my best interest at heart. And I think we need to do more than that. I think, you know, the third thing that we recommended was that they really need to be a database and a research about again best practices in the area of communication and behavior change, because, you know, health professionals are not always the best communicators we need to really figure out what's, you know, how do we use communication technology in a way that really delivers messages. Would any of you support compulsory vaccination when we reach that point. I'll jump in. No. Yeah. It's very hard to I mean, they're the first of all it's a emergency authorization, not a full approval, it is still technically experimental. And we're still having to gather information and data about what what's happening now with 40 million vaccinated in the United States plus, you know, many times that many around the world. We're now not seeing the rare kinds of things that can emerge that are dangerous or alarming. And that's excellent. And that'll give people much more confidence. I think the powerful thing that we're seeing that it's related to Helene's point is that we have not had the advocacy campaign that goes out and it's been stymied in some extent to some extent by the lack of supplies and the Biden administration is held back on saying hey let's let's encourage people to go get a vaccination they can't get the. But at the same time what we've always known is that knowing somebody who has been vaccinated and your clinician and what they think about it are the two things that make the biggest difference and as people have gotten to know somebody who's been vaccinated that has made a huge change so we went from pretty high levels of vaccine hesitancy and it's worth distinguishing between the people who are hesitant and want to wait or see more data and those who are actually against vaccination. But both of those groups the vaccine hesitant and the anti vax numbers were high the people had said I I will not be taking the vaccine and you know I might be taking the vaccine but I want to see more. Those numbers are down so that we're below 10% now in the in the black community and in other groups that have been very strongly opposed are now less opposed people are more likely to know somebody who's been vaccinated and then the fear is dropping that said if you are reaching less people of color they're less likely in those communities to know someone who's been vaccinated and you start falling further behind, which is the situation we have been in. There's lots of interesting things to talk about if we want to get to it about what does seem to be working to reach those populations. Yeah, just to say, I would totally agree and I think it's more the carrot than the stick. I don't you know I think that it again given right information given the right messengers done in a way that is appropriate that respects people's autonomy and dignity. I think most people will want to take this vaccine for those who have a reason that they don't. I think we should honor and respect people's ability and that and also recognize that this, you know, do a tools point that this is a moving train. You know what we saw huge hesitancy when there was no vaccine when it was theoretical and how that shifted once we had a vaccine was so effective and efficacious that that, you know, it really changed people's minds and so I don't think a no necessarily means a never. And I think we should give people the respect to make up their minds when they make up their mind. And I don't, you know, there isn't a medical intervention that is compulsory otherwise and so I'm not sure this would be the one to start I think it. You know, there's, there's enough time for people to make up their minds in the meantime. But there are some like, you can't enroll your kids in public school if they don't have certain vaccines, for example. So, I mean there are there are ways you can actually get I mean there you can get exemptions. I think that I think here one of the challenges we'll have is around healthcare workers and whether they, you know, they, we have more and more healthcare institutions that mandate flu vaccination, so that they're not passing it on to their patients. Now, one of the things about the vaccine, we don't know that it reduces, you know, stops transmission. So, you know, at this point, it's only about whether you're protecting yourself from getting sick. We believe it will also knock down transmission and we'll have much more data about that in the next month or two. And then the challenges will become, you know, the nursing home worker, the ICU worker, and what those options are.  And it's been far more effective to, you know, use every method of persuasion, accept coercion in those kinds of efforts. Whether you have privileges, like, you know, being school attendance that has higher bar to withdraw from not doing it, or flying on airplanes or things like that, those will become contentious issues and right now, I think it is absolutely critical that we bring everybody on board without making them feel that they're being forced to take a still a vaccine. We have a lot of information about it's clearly better to get the vaccine than to get the coronavirus. But, but we have more that we'll still have to learn. It's interesting hearing you both talk about the vaccine acceptance as really societal change like any any kind of societal change that when you know somebody who's had a personal experience that that really makes a difference. I think that's just an interesting parallel. I think it reduces the fear because fear is behind a lot of this. And so I think it reduces the fear to see somebody, you know, somebody like you somebody who you trust doing fine afterwards. I think it reduces a lot of that and you know I think the combination between reducing fear and increasing information. You know, a lot of the early hesitancy was really around things that were all that that were more rooted in things that could be true. So, as an example, the fact that this is an mRNA vaccine, people made the link that there could be some genetic outcomes as a result of that well that's not so far fetched, but it is also something that you can then talk through the rationale why in fact, even though it has RNA attached to the name, why that is not genetically altering yourself, but you know and so I think there's a lot of the reasons why people have concerns that are linked to things that you can actually provide facts to get people to the other side of it and so I think, you know, the burden of proof is on all of us to make sure we're giving the right information, make sure that we're making it accessible to people, because I, you know, I think again, most people provided with the right information and taking out some of that fear will really affect opt to take the vaccine. But if we tell people you must, it is going to create a lot more of a hurdle than providing the right kind of information to help people understand what the value is for them. I'd just like to note for our audience that in maybe five minutes or so will be transitioning over to Q&A so if you have any questions for our great panelists now is the time to drop them into that handy Q&A box. I want to shift gears a tiny bit to talk about the other vaccines and the pipeline. Do you think that we're going to be seeing, you know, the AstraZeneca vaccine here soon? Are you expecting that we're going to be able to approve more soon? Or do you think that we'll have a different sort of vaccine regimen here than elsewhere in the world? First of all, Johnson & Johnson has submitted its data to the FDA. They'll be reviewing it next week, I believe on the 25th or the 26th. And a few days after that will be a decision about whether Johnson & Johnson's one-shot refrigerated lower cost vaccine will get approved. And I think it will be approved and make a very big difference. The prospect of a one-shot refrigerated vaccine really changes your ability to distribute, including get to the homebound and others. That's very important. Novavax has had some very good results and is a protein-based subunit vaccine, has parts of the proteins in the virus that your body reacts to, and that is something we know how to produce and have produced in mass quantities before. So the Novavax vaccine, I think they expect to be closing their trial in the next month, and that will also offer a lot of potential. The AstraZeneca vaccine has not been submitted to the FDA, and they're completing a U.S. trial, I suspect, by April. We'll see results there. So we really could have five vaccines that will be ready to roll by the time we get to the general public. It will provide much more supply. It will certainly create a certain amount of confusion with people wondering, you know, do I take this one or that one? And does it make a difference? One thing I put in an op-ed with several colleagues in USA Today last week was that when you get a choice for a vaccine, the best vaccine is the one you can get compared to the coronavirus at this moment. My biggest concern is the strains, and the UK strain in particular, which is spreading rapidly across the United States, doubling every 10 days, 30 to 50% more contagious, and the vaccines are effective against it. So we need to be moving the vaccine out and making sure we're doing everything we can to keep the pedal going on our mitigation measures, too. And so we had a lot of criticism in the U.S. about how all of this is gone, but as Noah Smith and Bloomberg Opinion pointed out per capita, the U.S. has administered more vaccines to our population than all, but I think it's four other countries. Helene, do you have any thoughts about what the U.S. can and should be doing to make sure that the rest of the world gets better access to vaccines as well? Yeah, well, you know, obviously, no one is safe until everyone is safe. There is no such thing as wrapping ourselves up in some kind of COVID vaccinated bubble that the U.S. that can't be permeated. So, you know, I think it's important for us to remember that we need to also be thinking about the rest of the world, both because it's the right thing to do because we have many parts of the world that won't be able to afford vaccination for its population. And we have always been generous when it comes to global health, but it's also, you know, so it's the right thing to do, but it's also the smart thing to do because it's a global pandemic. And just as we're talking about strains, you know, from the UK and from South Africa and Brazil and, you know, we're talking about them because we know that they've already been introduced and they will only continue to be introduced. And so, you know, it will make a difference for all of us to make sure we all it's in all of our best interests to make sure that vaccine vaccination levels are as high around the entire world as possible. I also just think that is, you know, health has always been one of those areas where we can collaborate globally, even when we may not be able to collaborate politically on other issues and global health diplomacy is, you know, as it is called, is such an important aspect of our overall global role in the world. And so, you know, I think we have no choice. It was the right thing that immediately the Biden administration talked about reengaging with the World Health Organization, contributing to the vaccine covax facility, all of those things that I think will make a big difference for the safety of the world as well as our own safety. So I think we're going to transition to Q&A in just a second. But first, I wanted to ask all three of you a quick question, which is if you had the power to change one thing related to the vaccine distribution we're seeing now either something really small to do with the availability of gloves or something huge about making it a national rather than a state by state system. What would that be? You know, I guess I would say, I don't know, there is no one thing. So there is no one bullet that is a magic bullet that is going to make this all better. I think time is important. And again, while we've all been frustrated by, you know, maybe not perfect roll out, some of these things just take time. So I think one, you know, we need patience, we need to recognize that this is tough. I do think the supply of people is an important ingredient. And, you know, a tool mentioned it earlier, you know, being able to train a wider range of people to administer vaccines, I think is a very important part of this that we haven't paid as much attention. And that includes not only people to administer the vaccine, but people to outreach to communities. So I do think the people capacity aspect of this is an important one, along with supply, along with a better surveillance system, you know, all the things that we've talked about, but I guess those would be some that I would highlight. I'll jump in just to say, I think actually the administration is doing most of the things I would want to pull for, but one that I would say would be high on the list for me that I haven't seen yet plans about is really removing the billing component of setup it takes an enormous amount of work. It's a high cost, and it gets in the way of the resources and time for deploying the vaccine.  You know, we've seen this before with testing, lots of people got billed anyway, and it makes people very reluctant so I think there's some straightforward things that we could do that that access the resources that the insurers have in hand and have pocketed for that goal, but doesn't mean you're sending a bill one by one by one to everybody every for every vaccine administered. But I would just just to say, you know that was again one of our recommendations in our report is that there should be no out of pocket costs, including the administrative costs because that often gets forgotten and people make a big deal about the cost of the vaccine, but not the cost of the vaccine. And it then means that cash strap states, localities end up also being saddled with bills that are unnecessary so I think that is a huge issue that, again, it's not, it's not sexy it's not, you know, it's, it's kind of arcane for many people but it's So new America. Yes. And Hannah what would your one change be if you have one. The one thing I would love to see at the state level is, I would love for everybody who wants to sign up to be able to sign up. And I think that there and right now, the whole process is very reactive like, oh we got some more vaccines and so now we're opening up sign up. But we also know that we're in the middle of a mental health crisis, where people feel very hopeless and I think that if at least a date, even if it's like, maybe, you know, New York has estimated that my vaccine date is August. Fine. And maybe they're going to move it six times. Fine. As long as I know that they have me in the system, and that when it's my turn they'll let me I think that that would also on the other side, allow the states to see how many people are raising their hands, and how many people how much work they need to do, and to start proactively thinking about how to reach those populations. So that is my, you know, peace of mind for people, and also starting to think about doing outreach. Great. Well, I have about 7000 more questions for all of you, but I think I have to move to the audience now. Our first question, we got a couple of questions from anonymous people on zoom about the new strains we're seeing. Are there any concerns, for instance, on the use of the AstraZeneca vaccine when it sounds effective against B1351. I'll jump in on this one. Right now the. So yes, so B1351 is the strain in South Africa P1 is the strain in Brazil, both have some evidence of diminished effectiveness. There was a recent report from a study that's not. The methods are challenging to but raise the possibility of almost no effect from the AstraZeneca vaccine. South Africa has paused AstraZeneca routine distribution but scaled up, giving it to 100,000 people and monitoring what the outcomes are and that study is going to be critical because we really don't know what what I pay a lot of attention to is how effective are the vaccines in stopping what matters. Severe illness hospitalization death, and all of the vaccines have had a very, very, have been very effective against serious illness, including the AstraZeneca vaccine. The variants in South Africa and Brazil would be a concern, but the fact that that for B117 they have been equally effective in averting serious illness means I would not slow any of them down at all. Right now what we have is the UK B117 variant, moving very quickly across the US. It's 30 to 50% more likely to put you to to to infect you it's more contagious. And there's also now much more evidence that it's more likely to put you in the hospital or cause death, and we need to move the vaccines as quickly as possible. The other variants, we don't know as much about them are they more contagious do they spread more easily when compared with the others, and they just have arrived in spots here and there in the United States they're not widespread we clearly have to develop the the updated multi valent vaccines that have the ability to attack different versions of the virus, and those will count those are coming. The question comes from new America's own and Marie Slaughter, who asks, Do you see a possibility to use the systems that we're creating to distribute the vaccine as a basis for a renewed and stronger public health system, creating permanent positions for community health workers. Yes, for all of the above I mean I, and I think those are somewhat separate multiple different things in that, you know clearly. And I think I said this earlier, you know we really don't have a good system for adult vaccines, like we do for for childhood vaccinations and so I think this is a good opportunity to really build that because I think we're going to increasingly have diseases and epidemics that impact our whole population and so I think thinking about how are we using this to develop that system. I also think is the question implies is that there's also a job and an economic component to you know here in Chicago as an example, you know we've created a vaccine core that is both helping to on the vaccine effort, but it's also a way of getting people who weren't in the health care system into the health care system and then thinking about what's a career pathway beyond just developing helping with the vaccine effort so I think there's a there's both the health component, building that infrastructure, as well as, you know, looking at the economic, I will say, you know, every time we have something of a serious public health nature, and we say, this is the time that we're going to pay attention to the public health infrastructure and it doesn't happen. And so I just think I hope that we are really resolved this time to think about this because you know one of the biggest challenges for this is that we were caught off guard. We had not invested in our public health infrastructure, and we would have been so much better off had we had strong surveillance systems had we had strong testing capacity, had we had the kind of human resources and infrastructure that we need to mount a vigorous response so you know I do. I am hopeful that maybe this time we have learned enough lessons and it's been extensive enough that we will go ahead and make the investments in the public health infrastructure that we need. We are getting several questions from audience members about vaccination and children do you expect that we'll be seeing vaccines for children sometime in the near future or is that farther out. I mean, the tool you probably have a good sense as well, you know, probably within the next few months and you know what, often with with any medical intervention. First tried an adults and then gradually tried in younger and younger age people and so with this vaccine, you know, the trials did not include children did not include the pediatric age and there are now trials ongoing that will look at the next tranche down so the 16 to 12 and then ultimately 12 to, you know, six, so that we will have that information and we don't have to do it all over again. You know it will really look at safety, look at how the immune response works in younger people, and then be able to authorize it for pediatric use but that should be within the next few months that we have will have some of the data, because those trials are ongoing. The earliest one is Pfizer, which will have their results for their 12 to 16 population. Not until summer they reported a couple days ago. So that means maybe late summer you'd see it for over age 12 Oxford just started the first trial I'm aware of in six year olds and up. So the six to 12 age group and below six will follow after that. And the critical thing I would say that makes clear is we will not have the whole country vaccinated at the end of the year. We will only just barely be rolling out for the pediatric population so vaccines are not going to be the only answer and the only part of our response we're going to need good therapeutics and continue to develop good treatments. And we're going to have to continue to figure out how we maintain ventilation and do all the things we need to do in schools and that means testing will continue to be a significant part of our, our world and that. And, and I'm worried because testing is way down. As people get vaccinated they're sort of saying, we don't, we don't, when they're not coming in for testing at the rates they should be. So, that's a concern. We're continuing to wear masks and distance and all the other things and I, you know, I think it just makes it another very important point is that as, as much as we know that vaccine is kind of the ultimate in, in preventing disease, and hopefully also in preventing infection that we don't let our guard down too early, you know, I'm already happening. Which is a big concern. It's, it's, it's hard to get these multi layered communications right but we've got to make sure people continue to also do the things that they were doing before vaccination. I think the really difficult thing that Helene is going to be that we're going to have gotten to the adults and we'll see the hospitalizations. You know, below flu levels, right. And, and once that happens, arguing that take off that we don't take off the mass arguing that we can't just be normal again and be in concerts and everything else, waiting for the kids. That's going to be that's going to be a big, a big debate. Yeah, along those lines, somebody asks, we've been told we'll need to keep masking and socially distancing after we get vaccinated. I've not heard much about when we'll be able to return to a more normal life. Could you give us some guidance and hope on this. Would you schedule a vacation for some time in 2021 or is that probably not realistic.  We're not safe until everyone is safe. And I think tools comments about the fact that children won't be vaccinated. You know, I, this is not going to be simple. I know everybody wishes that there was a straightforward simple. Read the tea leaves read the crystal balls and we can give you an exact answer. This is this is not an exact science. And we're going to be ramping up some things as we ramp down other things and we're going to have to deal, you know, except the fact that we are going to be kind of multi dimensional in the way that we're thinking about this. And know that we're going to have multiple phases of this going on at the same time, not it's just not simple. Yeah, I'm going to bet that I don't I do not think we'll be able to eradicate the disease. And given that we won't be able to, if that's the case, if we can't eradicate it, then it's going to be something like an endemic flu that goes through the population and changes over time. And if the hospitalization and death rates are low, below flu for that, then we're going to have that challenging discussion that we did over, you know, driving 65 miles an hour instead of 55 miles an hour. And that is the tolerable level of hospitalization and death that we, you know, is it zero, or is it, is it somewhere north of there, before we start returning to normal and that's going to be. That's, that's not just a public health question that's, that's a political question that we'll be working through. Yeah, I think the, as you mentioned, the focus on treatment is also important because I think, you know, we've kind of swung from one direction to the other, and not realizing that this is really about integrating all of the things that we have so it's not all vaccine or all treatment. It's really how are we thinking about these in an integrated fashion, along with, you know, mask wearing, you know, we know that mask wearing will help us with the flu, as an example. It, you know, I hope that while I know 100% of our population won't continue to wear a mask that because people have gotten into the habit of it. When flu season starts when cold season starts that people will think well you know maybe I should just put a mask because I'm coughing. Maybe I should, you know, not stand right up against somebody in the grocery store line because, you know, this can help so I just think we're going to move into a much more complex nuanced world when it comes to protecting population when this becomes endemic. Sounds like a vacation but expecting to wear a mask sounds fair. I would take that deal. I have about, again, lots of questions I would love to keep talking to you for several hours but you are very busy people so I will not do that to you. I wanted to thank you all so much for joining future tense and the public interest technology program at New America for joining us for this important discussion. Please follow these three on social media at Helene Gale at a tool underscore Gawande and at Hannah shank for more future tense events like our discussion next Tuesday on the future of entertainment please follow at future tense now. Stay safe everyone and have a great rest of your day and thank you again for joining us. Thank you.


Good morning cyber traders welcome back happy Monday everyone hopefully we had a great weekend I know I have a start work on my new garden. I'm going to share it on my home living. Took down the old one you probably saw the video on that I made a really nice little courtyard my kid got older. Took down the play sets I had to do something with it looking forward to it but you know what made it makes it more exciting is that I can go out there and do it because today is pretty a lot of good stuff going on. Lot of big runners up in the market this morning. I mean this PAW I'm going to talk a little bit about it. We're also going to talk about some of I mean like between this one wall all those California stocks did really well. Draft King did really well and there's a couple of other ones that are moving pretty nicely but but once again it's always good to see everyone good morning and look inside for a new week. Listen this is the time when the market gets really really volatile things start picking up what we got we got we got Memorial Day coming up on the 29th was about almost about three weeks away. Basically so a lot of action going to be happening big earnings week last week you saw what happened the market very very volatile market. Let me just show up to doubt really quick and show you what happened. I mean we're having some really really big swings 300 500 days down up all different ways. But but the big news is going to happen what's going to happen on I think it's on Tuesday or Wednesday where where Congress going to meet with the president see what the way they stand with the with the budget proposal. You listen I heard rumors I mean they were saying on TV that they won't pass the market drop like 50% I mean the market's going to tell you where they stand on this whole budget thing. So thing as great things about traders is that we want that volatility we want good news we want bad news we want all different types of things that can make the market move. Hey listen if you haven't learned it already look what happened all the bank stocks it's like it's always like a pattern right there's always something new. If it's not solar stocks it's not if it's not the bank stocks that are happening. If it's not COVID there's always something if it's not the cryptocurrency stocks that are moving. There's always something that's moving pretty exciting so once again that's why we hear here at Cybertry University that's why we work like a team you know what I mean that's really what comes down to it. By the way I want to talk really quick about the top three.  So anyway learning about short squeezes I know we do lessons on it and stuff like that you can also if you're watching on our social media you have a couple of things on our YouTube channel and everything else. Just basically go out there and watch it but we teach a lot about it and once again if you register on Wednesday this week actually we're going to be doing an open house so you got that little free live wet workshop on a top left hand corner if anyone's logged in just scan it with your phone and you'll get registered for it. All right in the meantime let's talk about what happened on Friday because there were a lot of really cool stuff that happened. Pete I'm not going to start with this one let me start with the other one KNG. Okay so DraftKing has been having a really good good move. Now once again you I know listen I know a lot of you here even on social media or maybe you're new here at Cybertree feel like everybody starts off with options. I don't understand why other than you're playing a poor man getting rich man's game. I have an old saying about options who's more wealthier the person owns owns the house or the person rents the house. Well stop renting all the time sometimes it's time to buy and there's time to rent. You want to be a good options trader you got to know how to trade first. Okay it's black and white you want to swing trade you got to learn how to day trade first because they trickle in into a swing trade. DraftKing was one of those stocks you know $10 stock up to 24 in the middle right in the middle of the year the stock took a very very big hit. You could see here the stock was holding the $80 price range starting to make a little bit of a comeback it's been holding here for a long time. The writing was right on the wall right there. So DraftKing's doing pretty well that that we traded on on on Friday had a really nice pop as a day trade. Not only is a swing trade the exact thing go from 23 to 25 not listen there was a lot better ones than that one. So let me bring a couple of NB was MBTX was the other one that we looked at on Friday. So that one moved pretty nicely this that was about almost 100% mover that thing was at the $2 price range. You can see it ran to $8 on a swing trade but on Friday it ran from middle of the day from 5 to 8 that was in bed Fubo FUBO.  It's going on the stock moved pretty nicely and then OX was another one that moved pretty nicely and then obviously all these that did really well. CME did really really good that thing ran from 34 to 39 lemonade right in the open thing ran from 14 up to 15. This one just came down crashing down pretty quickly and Shopify I mean Shopify has been a great swing trade short term swing trade had great earnings. It trickled in from the day before let me just show you what happened on Thursday. So you can see it right here and move pretty nicely from 54 up to 60 and then backed off a little bit went from 58 all the way to 61. Listen you know we're not a fan of Shopify because it is a little on the expensive side not really up forte but the stocks I want to talk about which are kicking it again is the bank stock. So wall is is obviously did really well on Friday started around 21 this thing was awesome. So for some of you that logged in you know that are new here to Cybertrain and we have some new trial members. I know that some of you watching social media. So this stock was all these stocks. I don't know what the hell was the news on these things but talking about frightening this thing ran from $26 and drop within it started going down for about maybe 30 minutes and all of a sudden 10 o'clock thing went from 21 down to $12. It was getting halted, halted, halted, halted this one on the other the one that really started was P was PACW. I mean that one also you could see it right here got halted 370 thing dropped down to 250 things got crushed but I guess somebody some fake news came out of there and then boom that things been doing great did well on Thursday.  You know this morning this thing is already at $8 you're talking about a 400% mover in less than you know two days. So once again we were trading these stocks. Okay. Now remember here's Cybertrain University. You know, we don't give you recommendations. We it's illegal to give you a recommendation. We're not registered. I know people do it but let me tell you what we do. We give you a watch list and guess what put it on your watch list because you know who we're watching know the most in people we're going to watch the orders.  When you look at the level four that's what it's all about. So we have the PACW we're going to put we're going to put back on a watch this wall that thing's already about four bucks walls on there. And there's a couple other ones in here that also put some bank stocks here. Key Bank is also making a little bit of comeback to a little bit more keys also going to go on. And I think at first he never opened up that buy out. I think that pretty much does all of them right there. We will keep that's all pretty much left. All right. Now there are all the stocks that are moving to this morning. So let's go through the big percentage gainer. So by the way, let me tell you about level four really quick. So what we got going on with the level four. This is a pretty cool sign that some of you who you never seen as before. There is literally a 200,000 shares seller right at 810. Okay. And there's another guy backing him for another 60,000 and 820. You got another 129,000. So for all you people out there. They want to focus on these Mr. Fibonacci's and all this stuff. All these indicators. I know sometimes the cyber group members get a kick at it. It's probably becoming an old joke and it's getting stale. But there are people here, cyber group members, you know, if you're in a trading room, you know that some people just don't get it when you see stuff like that. I mean, add that up. What is that? Like literally like what 200, 300, so 400,000 shares sitting out there. You know, that's where the writing on the wall comes in. Not as now, not as pretty on the wall, but PCW, there is. All right. There are a couple of the stocks. I also want to keep an eye on to put on your watch list that aren't the big percentage gainers. So you got this stock that's doing phenomenal right now. Okay. So this stock right here is doing better than all the rest. Look at this stock of 70 cents. This thing is already up to a dollar eight. I gotta go find out where the orders are before we go crazy. Okay. What's the symbol on this? Let me look it up for you. BLCM.  That's where it comes out today. Okay. It's waiting for the data load up. Let's see what we got going on. Oh, beautiful. Okay. So we got a big order just showed up right here. You can see for about 116,000 at a dollar. Not the prettiest, but what you're seeing right now is called program trading. Okay. It kicks in around nine o'clock. Now, by the way, did everyone get my mouse pad? I got to put the QR code. We just, by the way, I know a lot of you guys that ordered it. I feel bad. We just got them in. They're paying us to get, you know what happened? Everyone was making it and we're making it warm. So we finally found the old company that made it. So if you, the mouse pad tells you the best time to trade, the worst times to trade, you could see right there. Great time. Right there. Program trading nine o'clock. That's what's driving this stock up there. See him clear his day at 98 cents. So nice little run up right there. Boom. You can see it did a little bit of a shake, shake and bake thing took off. Nice little move right there. Biggest percentage gainer. Couple of stocks also moving. I know you guys as cyber traders, you were looking at this stock. I am RN. You know what? It's kind of flat. It was moving. Okay. But it's not moving great. Same thing with easy FL. I know it's a 54%. I know a trade 2.4 million shares, but it's flat fourth biggest biggest. I know PCAW has warrants. Okay. So anyway, this, that's that one kind of made a move early. It's starting to trend down. Why is it trending down? Oh, I don't know because there's 400,000 shares out there. So we know where that's coming from. Couple of the stocks out in the big percentage gainers, not really that much. A lot of them a flat. Remember when you come back on a Monday over a weekend, not really that much going on. All right. Couple of the stocks out there. We'll keep an eye on on the New York stock exchange.  Six is moving, but the volume is pretty light. Walls already on there. We don't know. We already know about wall and looks like Boyle is trying to go back up. Boyle's been taking a very big hit lately. Stock hasn't gone anywhere. So I don't know if you probably heard to hear in New York, they got rid of gas for anyone that makes a building bigger, bigger than seven stories. So listen, utilities, if they're public, you know, they're going to make any killing. If you own gas, you know, they're not going to do too well. So all those gas stocks are going to really take big hits. And it's just, it just eventually keeps spilling in a little bit more and more. Let's get it. Don't get political, but just use that. I would agree and assault that when news comes out like that, it's going to affect. Keep an eye on space, by the way, because space is moving. We traded space many times. Virgin Virgin. And the stock took a very big, big hit. You could see here back in about a year and a half ago, it was like $60. Thing got crushed. I don't know. It just came up on my radar. It's up 7%, 3.7 million shares. By the way, the BC, the BLCM is not backing off. You can see it right here. It's still got to push. I'm getting a lot of orders coming in. All right. So listen, it's Monday, right? It's not a really big day. Not really anything crazy. We know we always find something that will pop up down the road. But the cyber traders, anyone in social media, anything I missed, anything you want me to look at before we end it and come back, because I don't really see that much other than these couple of stocks. The bank stocks, the ones in California stocks, Wall, PACW, and the BLCM, and then probably some of the other stocks. I think that pretty much does it. Oh, John, you did pretty well. John, the trade at IMRN, got in three trades, made about 84 cents. Beautiful. Way to go, John. He was actually in the cyber group room. Good for you. Nice. Way to go. All right. So let's get ready for the market open up. So let's get ready for a busy week. Once again, if you're watching social media, take out your phone. You got the QR code right there for the free workshop. Scan it. I see a bunch of viewers. Some of you already scanned it already. So we're live here every morning at 9am and at 2.30. We'll be back. Just make sure you like us. You friend us. But if you want to join that workshop, click on it. Cyber traders. Listen, I know we have a lot of new members that registered yesterday from last week. Welcome aboard. Very important. Everyone of you can get a phone call from Education Advisor. Let me give you the best experience possible so you know what to expect to be in your weekly trial in the trading room. Just all we want you to do is don't buy anything. Judges, not on our winners, but judges on our losers, okay? How we control them. Because it's not about making money. It's about controlling losses. And that's where people make their biggest mistake. So good luck, everyone. And all the cyber group traders, let's get ready to rock and roll and show them how we do it. All right, everyone, trade safe and everyone else. We'll be back here at 2.30.


Hi, I'm Zor. Welcome to Unizor Education. Today we will talk about continuity of the function. First of all, we are talking about real functions, which means their argument is real and their value are real. And this is basically within the framework of function limits, which is in turn part of the course of advanced mathematics for teenagers and high school students presented on Unizor.com. I suggest you to watch this lecture from this particular website because it has explanation and you can read it in the textbook. So, talking about continuity.  Well, it looks like the graph of such a function should be smooth, right? Which means you just continually drawing the graph of this function without lifting your pen. Well, it can be something like this. This is also continuous, but this is not. Because you have to lift the pen, put it in another point and then continue graphing the function. So, our intuitive understanding of continuity is basically drawing the graph of the function without lifting your pen from the paper or marker from the whiteboard. Alright, so let's try to explain this in more mathematical terms. First of all, let's talk about the main of these functions. Well, if I want to draw the graph without lifting my pen or marker, whatever, it means that it's supposed to be defined on a contiguous area, contiguous interval on the x-axis, right? Otherwise, I will have to lift my, if it's defined here and then here, then I have to draw the graph here, then lift my pen and start drawing there. So, if I don't lift my pen, it means my area where the function is defined, the domain of the function is a contiguous area. It can be finite, which means like from here to here, or it can be infinite from here to plus infinity or from here to minus infinity or from minus infinity to plus infinity. So, finite or infinite domain is the first requirement of this function. Alright, now, we finally have agreed that the domain is supposed to be a contiguous area on the x-axis. Now, how can I express mathematically, more rigorously, that the graph of the function is supposed to be drawn without lifting my pen? Well, as I approach any point on my graph, the next point is supposed to be exactly where my old points start, right? Which means basically that if I take two points, x1 and x2, and these are correspondingly f at x1 and f at x2. If my x1 and x2 are coming closer and closer, then my functions, my these points also supposed to come closer and closer. So, as I'm decreasing the distance between these, the distance between these two also is supposed to be getting closer and closer. So, if my x1 minus x2 goes to zero, which is an infinitesimal value, from this should follow that my difference between these two also is supposed to be infinitesimal. And what's also important, it should be actually for any position of my two points, x1 and x2, which I'm going to express slightly differently, but which means exactly the same thing. I will do the following. I'm saying that for any point r, which is a real number, which belongs to domain, which means that the function is defined, I can take x which tends to this r in any way, and it might be expressed as this. So, that's what I'm going to do. So, I'm fixing one point, but basically it can be any point. So, as soon as I fix this point r, then I can say that no matter how my x within the domain is approaching r, my function of x should approach function of r. So, first of all, it's defined at r because r belongs to domain, and the value is exactly the limit of the value of f at x. I will give you a couple of examples when it's not true, but my continuous function should actually have this particular property. And finally, let me express it in epsilon delta language, which is kind of customary for all these function limit kind of things. What does it mean? Well, it basically means that for any r, which belongs to domain, and for any epsilon, which is a positive number, however small, which basically dictates how close to each other will be the value of the function of point x and the value at point r. There exists such delta so that if my x minus r less than or equal to delta, then my f at x minus f at r by absolute value would be less than or equal to epsilon. So, that's what basically this mean on epsilon delta language. So, for any fixed r from domain and for any epsilon neighborhood around this, for any fixed r and for any value of the function, my epsilon neighborhood would be here from this function f at r up and down. There is always a delta neighborhood of r, so whenever my x within this delta neighborhood, my function values would be within epsilon. So, that's what actually mean in mathematical terms that you can draw the graph without lifting your hand. Quite frankly, this is nice and looking very impressively mathematically. I kind of prefer this type of notation. From this follows this, where r is any. And this is just basically an explanation what this arrow means. Epsilon delta, that's what it is. So, this is basically the definition of continuous function. Now, the function which usually students deal in school and universities maybe, they are mostly continuous. There are some examples. I will give you a couple of examples which is not the case. But generally speaking, what people are dealing with in mathematics and in mathematical applications, usually the functions are continuous. But anyway, obviously there are some exceptions. And what I'm going to do right now is just I'll give you a couple of examples of continuous and non-continuous functions. So, you basically have a feeling of how to prove the continuity of the function. My first example is function f at x equals to x cube. Well, the graph of this function, as you know, is something like this. Obviously continuous, right? So, how can I prove that this is a continuous function? Well, let's just use my epsilon delta definition. Choose any point r and any degree of closeness epsilon positive, which I would like to have between the value of the function at point r and the value of the function at point x. So, that's supposed to be less than or equal to epsilon. I have to find delta such that if my x minus r less than delta, then this would follow. That's what I have to do. I have to find delta. So, based on r and epsilon, I have to find delta. So, that this is from this follows this. Okay, let's just find it. I mean, how can I prove that this is continuous function? Well, I choose any r and any epsilon and they'll just come up with exact value of delta, which basically cause from this inequality to be this one to be true. Alright, so, x minus f of r is what? It's x cubed minus r cubed, right? By absolute value. Now, x cubed minus r cubed is basically, we all know this. Again, if you don't believe, just multiply it. But we did it many times. Now, and that means absolute value of the product is the product of absolute value less than or equal to. Now, this is sum of certain numbers. Now, some of them may be positive. Now, this is positive. This is positive. But if I will replace it with individual absolute value, I will only increase, right? The sum. This is greater or equal to this. If r and x are positive, then there is an equality. If r and x are negative, it's also equality because this is positive and this is the same as this one. But if r and x are of different signs, then this is definitely greater than this. So, that's true. Now, here is what I'm suggesting to do. Let's choose delta 1, something close to r, let's say equals to r. Why do they choose it? Because I would like this thing to be bounded from above, not exceeding certain value. Because this is obviously going to zero, right? So, I would like to exploit this, but I would like this to be relatively bounded. Because if this is an infinitesimal and this is bounded value, then their multiplication will be infinitesimal, right? So, if I choose, let's say, delta 1 equals to r, what does it mean? From this, now, this is what does it mean? It means that x is in delta neighborhood of r. So, if this is r and this is r minus delta and r plus delta. Now, if my delta 1 is equal to r, so it's from r minus r to r plus r. So, I definitely know that I am less than 2r by absolute value, at least, right? So, my x by absolute value would be less than or equal to 2r from this, right? If my x minus r less than delta 1, then I know this. So, let's choose it this way. Then I know that this is x minus delta times, now, x square would be 4r square plus 2r square plus 1r square. So, it's 7r square. I don't really need absolute value because this is square. Now, what I will do is I will choose delta 2, which is equal to epsilon divided by 7r square. Now, then there are multiplication if my x minus r is less than delta 2, which is equal to this. Then I definitely have this would be less than epsilon, right? That's what I need. Now, what I am going to do, I will choose the minimum between delta 1 and delta 2. Then I know that both actually will be true. This will be true and this will be true. And that's why it's less than epsilon. So, I explicitly found it's a minimum between r and epsilon divided by 7 divided by r square. This is exactly the delta which I am looking for. So, for any r and epsilon I found exactly the delta which is needed. Delta is minimum of r comma epsilon divided by 7r square. That's it. So, I found and from this follows this, which is this. Okay. So, I have proven that x cube is a continuous function. Let's talk about something else. Let's have another function, another example. Sin of x. Okay. Again, we know that the graph looks like this, right? Which is a continuous function. Now, we would like to prove it. Okay. So, let's first analyze what do we have to prove? Well, again, we choose r and choose epsilon. Now, what we have to do? We have to find such delta that this would be less than or equal to epsilon if x minus r delta. Okay. So, what is my delta? Let's just think about it. Well, my analysis actually is to transform this into something more palatable. Now, the difference between two signs. Well, if you remember trigonometry what we can do in this particular case is the following. We can have x is equal to x plus r divided by 2 and x minus r divided by 2. r is equal to x plus r divided by 2 minus r divided by 2, right? x would cancel and r would be r, r2 and r2. This is x2 and x, yes. And now, I will transform sin of x as sin of sum of these and sin of r as sin of difference between two these. And you will see that the final formula will be, well, let me just, sin of sum is sin cosine, cosine sin. So, sin x plus r cosine x minus r plus cosine sin. Cosine x plus r2 sin x minus r2. Now, that's my sin of x. Now, minus sin of r, sin of this one, which is sin x plus r cosine x minus r minus sin x minus. Sorry, sin cosine cosine x plus r sin x minus r. Now, why did they do all this? Because of this. And this is plus, by the way, because minus and minus. We have to subtract this minus and this minus would be plus. So, the answer is 2 cosine x plus r2 and sin x minus r2. Okay. Now, why is it better? For a very simple reason. Because now, I can say that this thing is less than or equal to absolute value of this is product of absolute value. Cosine is always from minus one to one. So, the cosine has absolute value of maximum absolute value of one. So, I can put two and then sin x minus r2. Right? So, instead of cosine, I took it maximum of its absolute value, which is one. Now, let's talk about this one. Sin phi less than phi. How about this for inequality? And I think you should remember it from definition of the sin. Remember, with unit circle, if this is my angle phi in regions, then the length of this is also phi. Because the circle has reduced r. Right? 2 pi r is the length of an entire circle. r is equal to 1. So, it's the length is 2 pi.  Right? So, it's the length of 2 pi and the total angle is 2 pi. So, if the angle is phi, then the length is phi in regions. And what is sin? Sin is this one. This is sin. Now, the length of the arc is greater than the perpendicular. Because the perpendicular is the shortest distance from the point to the line. And this is not the perpendicular, so it's always greater. than sin phi. So, I can say in this particular case that this is less than 2. And instead of angle, I will put sin of angle, put angle itself. x minus r divided by 2, which is x minus r. So, as a result, what I can say is the following. I will just choose delta equals to epsilon. And since I have this inequality, this is less than delta. Therefore, this would be less than epsilon. That's how we have proven this. And final example which I would like to present is a very simple example of a function which does not have this property of continuity. So, I have to express graphically, I have to lift my pen. So, let me just show you how I can define this function. So, let's have a function which is always equal to 0, except at one point. Here, it has the value of 1. So, f at x is equal to 0 if x is not equal to 0. And f at x is equal to 1 if x is equal to 0. So, my function is as follows. I have a graph here, but I do not go into this point 0. I have to jump, put a point here. And then I start again and put it. So, I put little errors here. And that's how usually we know that there is no point in between and the point is somewhere else. So, this is a typical example of the non-continuous function. How can I prove it? Well, very simply. Remember, we have two major requirements. Number one, domain should be contiguous. Now, in this case domain is all the real values from minus infinity to plus infinity. So, it is contiguous. The first requirement is satisfied. The second requirement is if x goes to r, therefore f at x goes to f at r. Now, let's take r is equal to 0. So, x goes to 0 as x goes to 0. My function at x should go to f of 0 which is equal to 1, right? But f at x as x getting closer and closer to point 0 is always equal to 0, you see? So, it is 0, 0, 0, 0 and the limit of 0 is 0. So, this is actually it goes to 0, not to 1. So, that's basically the proof. The second requirement of continuity is not satisfied. We have a sequence which goes to a point 0 where the limit is not equal to the value of the function at this point. By the way, if you will take, for instance, any other point, that would be a point of continuity. So, I have only one point where the function is not continuous. Just as a, well, mathematical joke, if you wish. I would like to find the function which is not continuous at any point. Can that be done? Well, apparently, yes. Consider function which is equal to 0 if x is rational and 1 if x is irrational. So, at any point, wherever you are, if you go by rational points, if you approach to this point, then you will have 0s and the limit will be 0. If you approach by irrational points to the same point, you will have 1, 1, 1, 1, 1 and the limit will be 1. So, basically, there is no limit. Whenever you approach this point and any point, there is actually no limit. So, we are not talking about function tending to any value at all. Which means, at every point, wherever you point, with every point, it is a point of non-continuous, not continuity. Non-continuous, whatever. It is a non-continuous point. All right, so, I suggested to read the notes for this lecture. They are basically expressing the same ideas and the same approach I did in the lecture. They are unizord.com. And, well, that's it. Thank you very much and good luck.


Network PFNN headline news update Welcome folks. We had the doubt down industrials finished down 22 Nasdaq up for S&P's flat What you had out here today folks is that you had a sideways market light volume Well, we did have into the clothes out here is that you know the Nasdaq the NDX 100 and this is always pretty easy to do Bottom line is that they sold that down pretty dramatically in the last 10 minutes We had the high today out there about 86 12 and in the last 10 minutes. We just went from 8600 to 85 81 so that's quite that's quite a pullback You know fast and furious no doubt about that but that being said bottom line This is the beginning of holiday trading folks. Okay, you're gonna see that inside the spy tremendous contraction of volume and no doubt it's early, but guess what pretty pretty easy to do We did 42 3 million shares in the spies that made a new high yesterday did 61 million the prior day you did 82 notes and bonds bottom line they pulled back into their Downdraft from last Friday. That's where they had rejected lower price. They still had volume out here We had the 10-year down 8 ticks the 30 year off 28 6 both cases Dramatically light of volume. That's in that they still want higher price lower yield King dollar King dollars up 158 ticks trading at 97 381 King dollar isn't a tire range right now bottom line We'll see what they can stay in the higher range and what brought the dollar higher Was the fact that the British pound yesterday? That was one of the biggest moves. It was the largest move actually in one year on the way down We went from the 135 mark into the 131 mark. We're 130 right now the yen is at 109.57 of the pound is the Euro is at 111. We get over we take a look at the gold market Would you have with the gold market bottom line gold market out here the physical gold market? that baby GCG that Traded flat out here bottom line that is still building cause for higher price. We're at 14 79 like to set up I suspect we're gonna be going higher in the next couple days. Have a great night folks Have a safe night come back and visit us right here 9 o'clock tomorrow morning. I man mr. Larry pesavento kicks us off TFNN has put together the best


It's important that you know the route, so in case you get separated you don't have a link back up. So overall it's going to be 18,000, 3.1, that's the intersection that we're on. We're also 37th Street. We're going to take a right on 37th Street and all the way up to South Range Road.


Okay, um, Beauregard is one of the most widely grown in the U.S. right now. It's probably what you get in your grocery store. Yeah, that's it. Oh, okay. Tastes like Thanksgiving. What else? Anything else? It's a good one to start with because it's like the baseline of sweet potato. You know? Mm-hmm. So that's just a olive oil and salt and pepper. This is butter, salt and pepper, mashed. So it's like just basic, nothing. Salted butter. It needs more? No, it's very salty. Oh, okay. Sorry. That's okay. Oh, that's not gonna distract. No, but it's good. No, it's good. Okay. Tell me about the hardiness of growing this type of sweet potato. No, I'm serious. That's something to consider, right? I don't know for this one yet because this one I'm waiting to get the variety back from the grower. I called him today. That is... So I don't know about the Japanese one. This is Beauregard. It's fast growing. So like, I think it was like 80 days or something versus the garnet, which is like 120 days, which might be too long to grow in Wisconsin. So, yeah, it's got a whole bunch of mites or not mites, resistances for rot and things like that. Can you do anything with the leaves? I think you can do something with all the leaves. Okay. I don't know. Okay. Jewel? What's special about the jewel? I don't know. I couldn't find much. Is it sweet here? It's not as sweet. I don't think it's... Less sweet? I think it's less sweet. Yeah. It's less sweet. It's more starchy. Mm-hmm. Oh, yeah. Beauregard's whiffleer. But that might be what you want in like a mashed potato replacement. Less sweet, more starchy. It depends on what you're going for because you're going to have white potatoes too. Yeah, potentially, yeah. So... But I mean, it depends on what you want for the sugar content. Yeah. Because if you want higher sugar content, then you just add brown sugar. That's true. That's definitely sweeter. Or this one, Beauregard, is definitely sweeter. Sweet potato pies are supposed to be sweet, is that right? I don't know. All right. If you have a pie that's not sweet? Shepherds. Those are karnat. Yeah, well that's a pretty... Or still a lot firmer. Still a lot of sweet. This one is not exciting to me. It seems flavorless compared to the other one. Well, that one takes under 20 days to mature, so... So why would it take so long to mature and then not have any flavor? I don't know. But it might have more yield. Like, it might produce more because it has longer, but less flavor. Well, that's something for you to consider, so tell me about that. I don't know for all of them yet. I'm in the middle of research. I don't know all of it yet. I know Beauregard is really a high producer and I think the karnat is a pretty high producer, but they gave different figures. This is like this one, the resource I found said how many bushels per acre for this one and that one told me how many potatoes per plant. I don't know if this makes any difference, but these were all organic, right? Yeah. That one just seems flavorless. It's amazing. Yeah, all I could taste is butter. I don't taste any additional flavor from the potato itself. It seems a bit firmer. That one might need a little longer to cook. All right, I'm intrigued by the Japanese one. I'm a little disappointed at browning a lot, which is fairly typical to potatoes and other things when they're oxidizing out in the atmosphere. They'll turn brown like a banana. So you can see, like, this isn't white. When I first cut it open, it was like white like this, and now it's already fairly brown. Ooh. It's definitely the smoothest, because I did about the same amount of mashing for all of them. Did they all cook the same amount? Yep, they all cooked the same amount, all cooked exactly the same. Oil, butter, salt and pepper on all of it. This one's definitely not sweet. How's a better crisp on it? I think this would make better fries when they're super smooth. But my question is, if you have white potatoes as well, what would be the benefit of currently Japanese food? That's true. They're probably the closest to white potatoes. The color is part of the front, and let me ask you this, because color also has to do with nutritional value. So what's the nutritional value of the Japanese food? That I haven't looked up yet. Why can't you answer any of my questions? I don't know. Lots of carbohydrates and a few vitamins and minerals is what they're all going to be. But these must have some sort of different nutrient content because they're orange. Beta carotene, I'm guessing? I don't know. Yeah, I don't know. That's true since those are white and white. But I'm saying in terms of, particularly in the winter, from a nutritional standpoint, you know, you want your plate to be very colorful. In the wintertime, your plates are generally less colorful. So if you've got white potatoes already, then that's not going to add any color. I think they'll make the better fries though, but yeah. But so will white potatoes. Yeah, I know. Okay, so if we want sweet, we'd want to go borrow guard. Guard I think is out because it doesn't taste very good. I mean, it doesn't taste like anything. Unless there's some sort of benefit other than in the taste that we don't know about yet, because you haven't finished your research. Oh yeah, curious cancer Alzheimer's. That's what I'm saying. You know what I'm saying? It doesn't, don't. I think, yeah, you have to consider things other than taste. Yeah, and I feel like the Japanese is a lot softer and I feel like it would bruise a lot easier. And I noticed that like when they came in, who knows how they were handled, you know, compared that it's not a fair comparison because we don't know. But like this one had a lot more like spots and stuff on it, which could be again from different handling. So, you know, but it doesn't feel as like it preserves as well, which is another problem. If we're storing a lot of them, we'll go about halfway through the winter. Where, yeah, the garnets, three, two, at least two are about the same. So, I like. I mean, I'm going with one of these two. I think it depends on what you want your sweet potatoes for if you want them sweet potato tasting and you have to go with the bober carb. But if you want something that's a little bit more versatile, you know, because this could be, you know, you add a little bit of sugar and it's like a sweet potato. You don't add any sugar and it's more like, you know, a butternut squash. And you can't take the sugar out of this one. But, I'm a sucker for sugar. What is it? Especially in the winter. Beauregard's kind of boring though. I wanted something like, oh, this is a super exotic amazing sweet potato from Sumatra and it's just the most amazing thing you've ever had. Not the Beauregard from Louisiana. Tell me about the jewel. Is it from Sumatra? Or is it from Ohio? And apparently there's also another type. There's two types of jewels and I don't know which one this is. Not a bad potato guide. I mean, so I think just based on taste alone you narrowed it down to these two and now you need to do further research into these two and decide which one is more about the jewel. Yeah, well, and we need to talk more about do we want something that's more, yeah, like you said, more versatile we can always add some honey or whatever to it. Well, and how much space does each plant need and how many does each plant produce. You know, which is the most space efficient if you have a small space. That's true. And which ones will vine like some will crawl up trellises and some won't, which will make a big difference for space. In vertical space we have a lot. We do. They're all good though. Yeah, I mean, what could be bad to potato with butter and salt? And pepper. Pepper. Beauregard or jewel. I don't know, I have a long rambly video. Oh, wonderful. It's just us talking about potatoes. Very exciting.